Wird geladen...
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
PD-1/PD-L1 checkpoint blockades have achieved significant progress in several kinds of tumours. Pembrolizumab, which targets PD-1, has been approved as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with positive PD-L1 expression. However, PD-1/PD-L1 checkpoint block...
Gespeichert in:
| Veröffentlicht in: | J Exp Clin Cancer Res |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6380009/ https://ncbi.nlm.nih.gov/pubmed/30777100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1085-3 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|